TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

1.1022 Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am 2008;22:261-74. 1.1023 Strle F et al. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis 2006;43:704-10. 1.1024 Ljøstad U et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non inferiority, double-blind, randomised trial. Lancet Neurol 2008;7:690-5. 1.1025 Butler T. Plague into the 21st century. Clin Infect Dis 2009;49:736-42. 1.1026 Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166- 72. 1.1027 Prentice MB et al. Plague. Lancet 2007;369:1196-207. 1.1028 Mwengee W et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 2006;42:614-21. 1.1029 Tissot-Dupont H et al. Q fever. Infect Dis Clin North Am 2008;22:505-514. 1.1030 Marrie TJ . Q fever pneumonia. Infect Dis Clin North Am 2010;24:27-41. 1.1031 Hartzell JD et al. Q Fever: epidemiology, diagnosis and treatment. Mayo Clin Proc 2008;83:574-9. 1.1032 Raoult D et al. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005;5:219-26. 1.1033 Parker NR et al. Q fever. Lancet 2006;367:679-88. 1.1034 Maurin M et al. Q fever. Clin Microbiol Rev 1999;12:518-53. 1.1035 Terheggen U et al. Clinical manifestations of Q fever in adults and children. Travel Med Infect Dis 2007;5:159-64. 1.1036 Gikas A et al. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 2001;45:3644-6. 1.1037 Raoult D et al. Treatment of Q fever endocarditis. Comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999;159:167-73. 1.1038 Raoult D et al. Q fever during pregnancy. Diagnosis, treatment, and follow-up. Arch Intern Med 2002;162:701-4. 1.1039 Carcopino X et al. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis 2007;45:548-55. 1.1040 Dworkin MS et al. Tick-borne relapsing fever. Infect Dis Clin North Am 2008;22:449-68. 1.1041 Larsson C et al. Current issues in relapsing fever. Curr Opin Infect Dis 2009;22:443-9. 1.1042 Cutler SJ et al. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect 2009;15:400-6. 1.1043 Assous MV et al. Relapsing fever borreliosis in Eurasia: forgotten, but certainly not gone! Clin Microbiol Infect 2009;15:407-14. 1.1044 Cutler SJ. Possibilities for relapsing fever reemergence. Emerg Infect Dis 2006;12:369-74. 1.1045 Hasin T et al. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. N Engl J Med 2006;355:148-55. 1.1046 Walker DH. Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis 2007; 45(suppl. 1):S39-44. 1.1047 Botelho-Nevers E et al. Fever of unknown origin due to rickettsioses. Infect Dis Clin North Am 2007; 21:997-1011. 1.1048 Jensenius M et al. Rickettsioses and the international traveler. Clin Infect Dis 2004;39:1493-9. 1.1049 Walker DH. Rickettsial diseases in travelers. Travel Med Infect Dis 2003;1:35-40. 1.1050 Parola P et al. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev 2005;18:719-56. 1.1051 Chen LF et al. What‘s new in Rocky Mountain spotted fever? Infect Dis Clin North Am 2008;22:415- 32. 1.1052 Masters EJ et al. Rocky Mountain spotted fever. A clinician‘s dilemma. Arch Intern Med 2003,163: 769-74. 1.1053 Minniear TD et al. Managing Rocky Mountain spotted fever. Expert Rev Anti Infect Ther 2009;7: 1131-7. 1.1054 Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis 2007;7:724-32. 1.1055 Rovery C et al. Questions on Mediterranean spotted fever a century after its discovery. Emerg Infect Dis 2008;14:1360-7. 1.1056 Rovery C et al. Mediterranean spotted fever. Infect Dis Clin North Am 2008;22:515-30. 1.1057 Cazorla C et al. Tick-borne diseases: tick-borne spotted fever rickettsioses in Africa. Infect Dis Clin North Am 2008;22:531-44. 1.1058 Roch N et al. African tick bite fever in elderly patients: 8 cases in French tourists returning from South Africa. Clin Infect Dis 2008;47:e28-35. 1.1059 Paddock CD et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis 2004;38:805-11. 1.1060 Paddock CD et al. Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted fever. Clin Infect Dis 2008;47:1188-96. 1.1061 Bechah Y et al. Epidemic typhus. Lancet Infect Dis 2008;8:417-26. 1.1062 Lutwick LI. Brill-Zinsser disease. Lancet 2001;357:1198-200. 1.1063 Civen R et al. Murine typhus: an unrecognized suburban vectorborne disease. Clin Infect Dis 2008; 46:913-8. 1.1064 Pérez-Osorio CE et al. Rickettsia felis as emergent global threat for humans. Emerg Infect Dis 2008; 14:1019-23. 1.1065 Kelly DJ et al. Scrub typhus: the geographic distribution of phenotypic and genotypic variants of Orientia tsutsugamushi. Clin Infect Dis 2009;48(suppl. 3):S203-30. 1.1066 Phimda K et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007;51:3259-63. 1.1067 Kim YS et al. A comparative trial of a single dose of azithromycin versus doxycycline for the treatment of mild scrub typhus. Clin Infect Dis 2004;39:1329-35. 1.1068 Benenson S et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001;110:60-3. 1.1069 Thomas LD et al. Tularemia pneumonia. Infect Dis Clin North Am 2008;22:43-55. 1.1070 Nigrovic LE et al. Tularemia. Infect Dis Clin North Am 2008;22:489-504. 1.1071 Hepburn MJ et al. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther 2008;6:231-40. 1.1072 Ellis J et al. Tularemia. Clin Microbiol Rev 2002;15:631-46. 1.1073 Sobel J. Botulism. Clin Infect Dis 2005;41:1167-73. 1.1074 Kongsaengdao S et al. An outbreak of botulism in Thailand: clinical manifestations and management
of severe respiratory failure. Clin Infect Dis 2006;43:1247-56. 1.1075 Koepke R et al. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008;122:e73-82. 1.1076 Rowley AH et al. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197-203. 1.1077 Pinna GS et al. Kawasaki disease: an overview. Curr Opin Infect Dis 2008;21:263-70. 1.1078 Son MB et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009;124:1-8. 1.1079 Newburger JW et al. Diagnosis, treatment and long-term management of Kawasaki disease. Circulation 2004;110:2747-71. 1.1080 Burns JC et al. Kawasaki syndrome. Lancet 2004;364:533-44. 1.1081 Mason WH et al. Kawasaki syndrome. Clin Infect Dis 1999;28:169-87. 1.1082 Burgner D et al. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis 2005;9:185-94. 1.1083 Esper F et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499-502. 1.1084 Kobayashi T et al. risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009;28:498-502. 1.1085 Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3. 1.1086 Sundel RP et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-6. 1.1087 Newburger JW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75. 1.1088 Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007;356:659-61. 1.1089 Furukawa T et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. 1.1090 Wallace CA et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:e78. 1.1091 Hashino K et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7. 1.1092 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68. 1.1093 Cilliers AM. Rheumatic fever and its management. Br Med J 2006;333:1153-6. 1.1094 Lever A et al. Sepsis: definition, epidemiology, and diagnosis. Br Med J 2007;335:879-83. 1.1095 Holmes CL et al. Vasopressin. Semin Respir Crit Care Med 2004;25:705-11. 1.1096 Russell JA et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. 1.1097 Levy MM et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010;36:222-31. 1.1098 Garnacho-Montero J et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.Crit Care Med 2003;31:2742-51. 1.1099 MacArthur RD et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004;38:284-8. 1.1100 Kumar A et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.Crit Care Med 2006;34:1589-96. 1.1101 Ferrer R et al. Effectiveness of treatments for severe sepsis. A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861-6. 1.1102 Nguyen HB et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality.Crit Care Med 2007;35:1105-12. 1.1103 Drgona L et al. The need for aminoglycosides in combination with β-lactams for high-risk febrile neutropaenic patients with leukaemia. Eur J Cancer Suppl 2007;5:13-22. 1.1104 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;1:CD003344. 1.1105 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J 2004;328:668-81. 1.1106 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519-27. 1.1107 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003;326:1111-9. 1.1108 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-42. 1.1109 Rivers E et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77. 1.1110 Annane D et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 2002;288:862-71. 1.1111 Sligl W et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009;49:93-101. 1.1112 Minneci PC et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009;15:308-18. 1.1113 Annane D et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. A systematic review. J Am Med Assoc 2009;301:2362-75. 1.1114 Sprung CL et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111- 24. 1.1115 Keh D et al. Corticosteroid therapy in patients with severe sepsis and septic shock. Semin Respir Crit Care Med 2004;25:713-9. 1.1116 Bernard GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. 1.1117 Abraham E et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41. 1.1118 Houston G et al. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009; 15:319-24. 1.1119 Toussaint S et al. Activated protein C for sepsis. N Engl J Med 2009;361:2646-52. 1.1120 Nadel S et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-43.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23: 1.970 Thomas RJ et al. Current mana
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76:
18.91 Lesho E. Evidence base for us
Page 77 and 78:
tients. J Antimicrob Chemother 2009
Page 79 and 80:
duct characteristics. Available at:
Page 81 and 82:
_Product_Information/human/000338/W
Page 83 and 84:
114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86:
North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?